Downloads

https://doi.org/10.53941/rmd.2025.100003
Xu, C., & Wu, Y. Underestimated Roles of Osteocytes in Medication-Related Osteonecrosis of the Jaw. Regenerative Medicine and Dentistry. 2025, 2(1), 3. doi: https://doi.org/10.53941/rmd.2025.100003
Volume 2, Issue 1, 2025
Copyright (c) 2025 by the authors.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Perspective

Underestimated Roles of Osteocytes in Medication-Related Osteonecrosis of the Jaw

Chunfeng Xu and Yiqun Wu *

Department of Second Dental Center, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Centre for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai Research Institute of Stomatology, Shanghai 201900, China

* Correspondence: yiqunwu@hotmail.com

Received: 18 February 2025; Revised: 10 March 2025; Accepted: 11 March 2025; Published: 14 March 2025

Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a grievous complication after the long-duration administration of some bone-modifying agents, mainly containing bisphosphonates (BPs), denosumab, angiogenesis inhibitors, immunosuppressors, glucocorticoids, and chemotherapeutics. Its prevalence is rare but mounting due to the widespread application of MRONJ-associated drugs in the aging population and cancer patients. Although MRONJ is excruciating, there has been no specific and efficient remedy for it. To date, the understanding of MRONJ is not thorough, and various theories on MRONJ have been proposed, among which impaired bone remodeling as a result of inhibited osteoclast generation and activity is the predominant one. However, the role of osteocytes in MRONJ has been omitted, given their crucial roles in governing bone metabolism: they not only communicate with osteoblasts for bone formation but also promote osteoclastogenesis.

Keywords:

osteocytes medication-related osteonecrosis of the jaw microdamage apoptosis inflammation

References

  1. Campisi, G.; Mauceri, R.; Bedogni, A.; et al. Re: AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update. J. Oral Maxillofac. Surg. 2022, 80, 1723–1724. doi: 10.1016/j.joms.2022.07.149
  2. Parfitt, A.M. The cellular basis of bone turnover and bone loss: A rebuttal of the osteocytic resorption—Bone flow theory. Clin. Orthop. Relat. Res. 1977, 127, 236–247. doi: 10.1097/00003086-197709000-00036
  3. Ru, J.; Wang, Y. Osteocyte apoptosis: The roles and key molecular mechanisms in resorption-related bone diseases. Cell Death Dis. 2020, 11, 846. doi: 10.1038/s41419-020-03059-8
  4. Moriishi, T.; Komori, T. Osteocytes: Their Lacunocanalicular Structure and Mechanoresponses. Int. J. Mol. Sci. 2022, 23, 4373. doi: 10.3390/ijms23084373
  5. Nakashima, T.; Hayashi, M.; Fukunaga, T.; et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 2011, 17, 1231–1234. doi: 10.1038/nm.2452
  6. Poole, K.E.S.; Van Bezooijen, R.L.; Loveridge, N.; et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005, 19, 1842–1844. doi: 10.1096/fj.05-4221fje
  7. Robling, A.G.; Bonewald, L.F. The Osteocyte: New Insights. Annu. Rev. Physiol. 2020, 82, 485–506. doi: 10.1146/annurev-physiol-021119-034332
  8. Xu, C.; Xiao, Y.; Wu, Y.; et al. Impaired Osteoclastogenesis in Medication-Related Osteonecrosis and Potential Clinical Management with BMP-2. Regen. Med. Dent. 2024, 1, 5. doi: 10.53941/rmd.2024.100005
  9. Niedźwiedzki, T.; Filipowska, J. Bone remodeling in the context of cellular and systemic regulation: The role of osteocytes and the nervous system. J. Mol. Endocrinol. 2015, 55, R23–R36. doi: 10.1530/JME-15-0067
  10. De Cicco, D.; Boschetti, C.E.; Santagata, M.; et al. Medication-Related Osteonecrosis of the Jaws: A Comparison of SICMF–SIPMO and AAOMS Guidelines. Diagnostics 2023, 13, 2137. doi: 10.3390/diagnostics13132137
  11. Zhang, W.; Gao, L.; Ren, W.; et al. The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw. Front. Immunol. 2021, 12, 606043. https://doi.org/10.3389/fimmu.2021.606043.
  12. Aguirre, J.I.; Castillo, E.J.; Kimmel, D.B. Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (MRONJ). Bone 2021, 153, 116168. doi: 10.1016/j.bone.2021.116168
  13. You, T.M.; Kim, H.S. Histopathologic Comparison of Osteomyelitis, Osteoradionecrosis, Medication-Related Osteonecrosis of the Jaw. Korean J. Oral Maxillofac. Pathol. 2015, 39, 551–558. doi: 10.17779/KAOMP.2015.39.3.551
  14. Kuehn, S.; Scariot, R.; Elsalanty, M. Medication-Related Osteonecrosis: Why the Jawbone? Dent. J. 2023, 11, 109. https://doi.org/10.3390/dj11050109.
  15. Sonis, S.T.; Watkins, B.A.; Lyng, G.D.; et al. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2009, 45, 164–172. doi: 10.1016/j.oraloncology.2008.04.013
  16. Kim, J.-W.; Tatad, J.C.I.; Landayan, M.E.A.; et al. Animal model for medication-related osteonecrosis of the jaw with precedent metabolic bone disease. Bone 2015, 81, 442–448. doi: 10.1016/j.bone.2015.08.012
  17. Mine, Y.; Okuda, K.; Yoshioka, R.; et al. Occlusal Trauma and Bisphosphonate-Related Osteonecrosis of the Jaw in Mice. Calcif. Tissue Int. 2022, 110, 380–392. doi: 10.1007/s00223-021-00916-2
  18. Aguirre, J.I.; Castillo, E.J.; Kimmel, D.B. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone 2021, 153, 116184. doi: 10.1016/j.bone.2021.116184
  19. Rao, N.J.; Yu, R.Q.; Wang, J.Y.; et al. Effect of Periapical Diseases in Development of MRONJ in Immunocompromised Mouse Model. Biomed. Res. Int. 2019, 2019, 1271492. doi: 10.1155/2019/1271492
  20. Takemura, Y.; Moriyama, Y.; Ayukawa, Y.; et al. Mechanical loading induced osteocyte apoptosis and connexin 43 expression in three-dimensional cell culture and dental implant model. J. Biomed. Mater. Res. A 2019, 107, 815–827. doi: 10.1002/jbm.a.36597
  21. Moustafa, A.; Sugiyama, T.; Prasad, J.; et al. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos. Int. 2012, 23, 1225–1234. doi: 10.1007/s00198-011-1656-4
  22. Pathak, J.L.; Bravenboer, N.; Klein-Nulend, J. The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases. Front. Endocrinol. 2020, 11, 405. https://doi.org/10.3389/fendo.2020.00405.
  23. Yan, Y.; Wang, L.; Ge, L.; et al. Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications. Curr. Osteoporos. Rep. 2020, 18, 67–80. doi: 10.1007/s11914-020-00564-9
  24. Li, X.; Zhang, Y.; Kang, H.; et al. Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling. J. Biol. Chem. 2005, 280, 19883–19887. doi: 10.1074/jbc.M413274200
  25. McClung, M.R.; Grauer, A.; Boonen, S.; et al. Romosozumab in Postmenopausal Women with Low Bone Mineral Density. N. Engl. J. Med. 2014, 370, 412–420. doi: 10.1056/NEJMoa1305224
  26. Nakashima, F.; Matsuda, S.; Ninomiya, Y.; et al. Role of sclerostin deletion in bisphosphonate-induced osteonecrosis of the jaw. Bone 2024, 187, 117200. doi: 10.1016/j.bone.2024.117200